TTAX-03 clinical trials
Also written TTAX03.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2021
How each study uses TTAX-03 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- TTAX03
- 2
Studies by the year they started
3 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
BioTissue Holdings, Inc (3)
Studies
Open first, then newest update. How each study uses TTAX-03 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03.CompletedPhase 2BioTissue Holdings, IncNCT06780306Written as TTAX03
- Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord (TTAX03) for KL Grade 3-4 Knee OACompletedPhase 2BioTissue Holdings, IncNCT05079035Written as TTAX03
- TTAX03 for the Treatment of Lumbosacral Facet Joint PainWithdrawnPhase 1BioTissue Holdings, IncNCT06236308Written as TTAX03 10mg